The relevance of iron in the pathogenesis of Parkinson's disease

被引:270
作者
Sian-Huelsmann, Jeswinder [1 ]
Mandel, Silvia [2 ]
Youdim, Moussa B. H. [2 ,3 ]
Riederer, Peter [1 ]
机构
[1] Univ Wurzburg, Sch Med, Natl Parkinson Fdn Ctr Excellence Labs, Clin & Polyclin Psychiat Psychosomat & Psychother, D-97080 Wurzburg, Germany
[2] Techn Rappaport Fac Med, Eve Topf Ctr Excellence Neurodegenerat Dis, Haifa, Israel
[3] World Cent Yonsei Univ, Dept Biol, Seoul, South Korea
关键词
ferritin; iron; iron-related disorders; neurodegenerative diseases; neuromelanin; Parkinsonism subtypes; HUMAN SUBSTANTIA-NIGRA; ALPHA-SYNUCLEIN; LIPID-PEROXIDATION; BASAL GANGLIA; BRAIN IRON; OXIDATIVE STRESS; NEUROMELANIN GRANULES; CELLULAR-DISTRIBUTION; DOPAMINERGIC-NEURONS; TYROSINE-HYDROXYLASE;
D O I
10.1111/j.1471-4159.2010.07132.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alterations of iron levels in the brain has been observed and documented in a number of neurodegenerative disorders including Parkinson's disease (PD). The elevated nigral iron levels observed in PD may reflect a dysfunction of brain iron homeostasis. Under normal physiological conditions excess iron can be sequestrated in ferritin and neuromelanin. Alternatively, the excess iron may represent a component of brain iron deposition associated with ageing. The aetiology of idiopathic PD largely remains an enigma. However, intensive investigations have provided a host of putative mechanisms that might contribute to the pathogenesis underlying the characteristic degeneration of the dopaminergic neurons in the substantia nigra (SN). The mechanisms proposed include oxidative (and nitrative) stress, inflammation, excitotoxicity, mitochondrial dysfunction, altered proteolysis and finally apoptotic induced cell death. Iron-mediated cellular destruction is mediated primarily via reactive oxygen or/and nitrogen species induced oxidative stress. Furthermore, these pathogenic mechanisms appear to be closely interlinked to the cascade of events leading to cellular death. There are conflicting reports about the stage during disease progression at which nigral iron change occurs in PD. Some have found that there are no changes in iron content SN in asymptomatic incidental Lewy body disease, suggesting it may represent a secondary event in the cascade of neuronal degeneration. In contrast, others have found an elevation of iron in SN in preclinical stages. These discrepancies may be attributed to the occurrence of different sub-groups of the disease. This concurs with the notion that PD represents a group of related diseases with a number of potential pathogenic pathways.
引用
收藏
页码:939 / 957
页数:19
相关论文
共 174 条
[1]  
Aime S, 2000, MOVEMENT DISORD, V15, P977, DOI 10.1002/1531-8257(200009)15:5<977::AID-MDS1032>3.0.CO
[2]  
2-Q
[3]   The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage [J].
Aleyasin, Hossein ;
Rousseaux, Maxime W. C. ;
Phillips, Maryam ;
Kim, Raymond H. ;
Bland, Ross J. ;
Callaghan, Steve ;
Slack, Ruth S. ;
During, Matthew J. ;
Mak, Tak W. ;
Park, David S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (47) :18748-18753
[4]   THE DETERMINATION OF HYDROXYDOPAMINES AND OTHER TRACE AMINES IN THE URINE OF PARKINSONIAN-PATIENTS AND NORMAL CONTROLS [J].
ANDREW, R ;
WATSON, DG ;
BEST, SA ;
MIDGLEY, JM ;
WENLONG, H ;
PETTY, RKH .
NEUROCHEMICAL RESEARCH, 1993, 18 (11) :1175-1177
[5]   Depletion of brain glutathione results in a decrease of glutathione reductase activity; An enzyme susceptible to oxidative damage [J].
Barker, JE ;
Heales, SJR ;
Cassidy, A ;
Bolanos, JP ;
Land, JM ;
Clark, JB .
BRAIN RESEARCH, 1996, 716 (1-2) :118-122
[6]   Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA [J].
Bartels, A. L. ;
Willemsen, A. T. M. ;
Kortekaas, R. ;
de Jong, B. M. ;
de Vries, R. ;
de Klerk, O. ;
van Oostrom, J. C. H. ;
Portman, A. ;
Leenders, K. L. .
JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (07) :1001-1009
[7]   MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects [J].
Bartzokis, G ;
Cummings, JL ;
Markham, CH ;
Marmarelis, PZ ;
Treciokas, LJ ;
Tishler, TA ;
Marder, SR ;
Mintz, J .
MAGNETIC RESONANCE IMAGING, 1999, 17 (02) :213-222
[8]  
BAUER M, 2008, BMC PHARM S1, V8, pA48
[9]   Iron status and neural functioning [J].
Beard, JL ;
Connor, JR .
ANNUAL REVIEW OF NUTRITION, 2003, 23 :41-58
[10]  
BECKER A, 1995, NEUROLOGY, V45, pA460